Claims-based pharmacy markers for comprehensive medication management program case identification: Validation against concurrent and prospective healthcare costs and utilization.

Res Social Adm Pharm

Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Center for Population Health Information Technology, Johns Hopkins University, Baltimore, MD, USA. Electronic address:

Published: October 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Three claims-based pharmacy markers (complex, costly and risky medications) were developed to help automatically identify patients for comprehensive medication management.

Objective: To evaluate the association between newly-developed markers and healthcare outcomes.

Methods: This was a two-year retrospective cohort study using PharMetrics Plus patient-level administrative claims in 2014 and 2015. We included all claims from 1,541,873 individuals with: (1) 24-month medical and pharmacy enrollment in 2014 and 2015, (2) aged between 18 and 63 in 2014, and (3) known gender. Independent/control variables came from 2014 while outcomes came from 2014 (concurrent analysis) and 2015 (prospective analysis). Three pharmacy markers, separately or together, were added to four base models to predict concurrent and prospective healthcare costs (total, medical, and pharmacy) and utilization (having any hospitalization, having any emergency department visit, and having any readmission). We applied linear regression for costs while logistic regression for utilization. Measures of model performances and coefficients were derived from a 5-fold cross-validation repeated 20 times.

Results: Individuals with 1+ complex, risky or costly medication markers had higher comorbidity, healthcare costs and utilization than their counterparts. Nine binary risky category markers performed the best among the three types of risky medication markers; the Medication Complexity Score and three-level complex category both outperformed a simpler complex medication indicator. Adding three novel pharmacy markers separately or together into the base models provided the greatest improvement in explaining pharmacy costs, compared with medical (non-medication) costs. These pharmacy markers also added value in explaining healthcare utilization among the simple base models.

Conclusions: Three claims-based pharmacy indicators had positive associations with healthcare outcomes and added value in predicting them. This initial study suggested that these novel markers can be used by pharmacy case management programs to help identify potential high-risk patients most likely to benefit from clinical pharmacist review and other interventions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sapharm.2022.04.006DOI Listing

Publication Analysis

Top Keywords

pharmacy markers
20
claims-based pharmacy
12
healthcare costs
12
markers
10
pharmacy
9
comprehensive medication
8
concurrent prospective
8
prospective healthcare
8
costs utilization
8
three claims-based
8

Similar Publications

Is the Time Right to Start Testing if Late-Onset Depression is Associated With the Development of an α-Synucleinopathy Like Parkinson's Disease? A Double Systematic Review and Meta-Analysis.

Am J Geriatr Psychiatry

August 2025

Department of Psychiatry (MLO, SEC, JZ, KS), Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Neuroimmunology Research Group (KS), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Psychiatric Program of the Netherlands Brain Bank (KS), Ne

Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development.

View Article and Find Full Text PDF

Objective: Aim: To evaluate clinical applicability of immune mediator's interleukin-16, immunoglobulin E along with eosinophil count in diagnosing COVID-19 and determining its severity.

Patients And Methods: Materials and Methods: Cross-sectional case-control study was conducted at Al-Najaf General Hospital, Najaf, Iraq between March and August 2024. 120 participants: 60 confirmed COVID-19 cases and 60 healthy controls which matched cases in terms of age and sex.

View Article and Find Full Text PDF

Objective: Aim: To investigate the role of serum vitamin D3 in the pathogenesis and diagnosis for hypothyroidism..

Patients And Methods: Materials and Methods: Cross-sectional study was conducted at the Outpatient Analytics Center of Al-Nokhba and Al-Sadder Teaching Hospital, Najaf, Iraq, between October 2021 and February 2022.

View Article and Find Full Text PDF

This review article, developed by the EASD Global Council, addresses the growing global challenges in diabetes research and care, highlighting the rising prevalence of diabetes, the increasing complexity of its management and the need for a coordinated international response. With regard to research, disparities in funding and infrastructure between high-income countries and low- and middle-income countries (LMICs) are discussed. The under-representation of LMIC populations in clinical trials, challenges in conducting large-scale research projects, and the ethical and legal complexities of artificial intelligence integration are also considered as specific issues.

View Article and Find Full Text PDF

This study aimed to investigate the therapeutic effects of Sini Decoction on a murine model of peripheral arterial disease (PAD) and to explore its potential mechanisms of action related to mitochondrial autophagy and M1 macrophage polarization. A total of 36 specific-pathogen-free Kunming mice were used to establish a PAD model and were randomly assigned into four groups: the experimental group (EG, administered Sini Decoction via gavage), the control group (CG, administered rapamycin via gavage), the model group (MG, administered 0.9% sodium chloride solution via gavage), and the normal group (NG, administered 0.

View Article and Find Full Text PDF